All In Biotech

Drug Trial Radar · NCT06021197

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia Patients During Symptomatic Remission

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 12, 2023

Primary completion

Dec 2027

Study completion Mar 2028

Sponsor

Lead sponsor
China Medical University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Science and Technology Council, Taiwan
First posted
Sep 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cognitive impairment, the core psychopathology of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission. While cognitive impairment associated with schizophrenia (CIAS) is an important therapeutic target, hypofunction of N-methyl-D-aspartate receptor (NMDAR) is a key factor of CIAS. This study aims to examine the efficacy and safety of an NMDA-enhancer (NMDAE) for the treatment of CIAS in schizophrenia patients during symptomatic remission.

Conditions

  • Schizophrenia

Interventions

  • NMDAEDrug

    Use of an NMDA enhancer for the treatment of CIAS

  • Placebo CapDrug

    Use of placebo as a comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of cognitive function compositeTime frame: Week 0, 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Psychiatry, China Medical University Hospital

    Taichung, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.